152 related articles for article (PubMed ID: 29281902)
1. Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy.
Xia Y; Du Z; Wang X; Li X
Hum Gene Ther; 2018 Feb; 29(2):242-250. PubMed ID: 29281902
[TBL] [Abstract][Full Text] [Related]
2. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-
Xia Y; Wang L; Ma X; Li X
Hum Gene Ther; 2020 Aug; 31(15-16):881-890. PubMed ID: 32013587
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
Qu H; Xia Y; Li X
Curr Gene Ther; 2020; 20(4):313-320. PubMed ID: 32851960
[TBL] [Abstract][Full Text] [Related]
4. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.
Xia Y; Li X; Sun W
Curr Gene Ther; 2020; 20(2):127-141. PubMed ID: 32951572
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of ASPP and P-gp to neoadjuvant chemotherapy combined with gene therapy in locally advanced cervical cancer.
Xiao J; Zhou J; Liang L; Liu F; Liang H; Xu C; Meng J
J BUON; 2019; 24(3):967-974. PubMed ID: 31424649
[TBL] [Abstract][Full Text] [Related]
6. Trans-arterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-center experience.
Liu Y; Zhang Y; Bautista D; Tang S; Zhou J; Li C; Zhao G
Cell Biochem Biophys; 2015 Jan; 71(1):99-104. PubMed ID: 25323562
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up.
Guan YS; Liu Y; Zou Q; He Q; La Z; Yang L; Hu Y
J Zhejiang Univ Sci B; 2009 May; 10(5):331-40. PubMed ID: 19434759
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Adenovirus-p53 Gene Therapy for Advanced Unresectable Soft-Tissue Sarcomas.
Xiao SW; Xu YZ; Xiao BF; Jiang J; Liu CQ; Fang ZW; Li DM; Li XF; Cai Y; Li YH; Sun Y; Su X; Zhu GY; Zhang SW
Hum Gene Ther; 2018 Jun; 29(6):699-707. PubMed ID: 29284287
[TBL] [Abstract][Full Text] [Related]
9. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.
Zhang WW; Li L; Li D; Liu J; Li X; Li W; Xu X; Zhang MJ; Chandler LA; Lin H; Hu A; Xu W; Lam DM
Hum Gene Ther; 2018 Feb; 29(2):160-179. PubMed ID: 29338444
[TBL] [Abstract][Full Text] [Related]
10. Synergistic gastric cancer inhibition by chemogenetherapy with recombinant human adenovirus p53 and epirubicin: an in vitro and in vivo study.
Xie YS; Zhang YH; Liu SP; Liu SQ; Peng CW; Wu L; Luo HS; Li Y
Oncol Rep; 2010 Dec; 24(6):1613-20. PubMed ID: 21042759
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy.
Smith HO; Stringer CA; Kavanagh JJ; Gershenson DM; Edwards CL; Wharton JT
Gynecol Oncol; 1993 Jan; 48(1):11-5. PubMed ID: 7678571
[TBL] [Abstract][Full Text] [Related]
12. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma.
Yang ZX; Wang D; Wang G; Zhang QH; Liu JM; Peng P; Liu XH
J Cancer Res Clin Oncol; 2010 Apr; 136(4):625-30. PubMed ID: 19882171
[TBL] [Abstract][Full Text] [Related]
13. Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer.
Liu S; Chen P; Hu M; Tao Y; Chen L; Liu H; Wang J; Luo J; Gao G
Cancer Gene Ther; 2013 Jun; 20(6):375-8. PubMed ID: 23722592
[TBL] [Abstract][Full Text] [Related]
14. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma.
Ma WS; Ma JG; Xing LN
Anticancer Drugs; 2017 Feb; 28(2):230-236. PubMed ID: 27775992
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
18. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran.
Ghaemmaghami F; Karimi-Zarchi M; Gilani MM; Mousavi A; Behtash N; Ghasemi M
Asian Pac J Cancer Prev; 2008; 9(3):421-6. PubMed ID: 18990014
[TBL] [Abstract][Full Text] [Related]
19. Uterine sarcoma-current management and experience from a regional cancer centre in North India.
Biswas A; Patel F; Kumar P; Srinivasan R; Bera A; Sharma SC; Rajwanshi A
Arch Gynecol Obstet; 2013 Oct; 288(4):873-82. PubMed ID: 23580012
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
